Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.
While the World Health Organization (WHO) has targeted the elimination of river blindness in most African countries by 2025, researchers from Erasmus MC, University Medical Center Rotterdam in the Netherlands and the Drugs for Neglected Diseases initiative (DNDi) have estimated that over 4 million people in West and Central Africa will still be infected with the disease in 2025 in areas where African eye worm is endemic.
In their modeling study, the researchers also found that 90% of these people will live in areas currently not covered by treatment programs for river blindness, posing a major challenge to the elimination of this disease.
River blindness is transmitted by the bite of an infected blackfly and causes severe itching, skin lesions, and eventually blindness. African eye worm gets its name from its most infamous tell-tale sign: the visible passing of the Loa loa worm through the eye. Individuals with a very high amount of Loa loa larvae (microfilariae) in the blood are at risk of life-threatening complications if they receive ivermectin, a drug for river blindness.
Mass drug administration programs of ivermectin need to be repeated for 10-12 years or more, as these treatments only kill the juvenile filarial worms that cause river blindness, and adult worms can live more than 10 years in the human body. Because of the risk of dangerous side effects, ivermectin cannot be safely used in areas co-endemic for river blindness and African eye worm and mass drug administration programs have not been started in some of these areas.
The current approach to preventing river blindness based on mass drug administration of ivermectin has been extraordinarily successful. But this study supports that alternative treatment strategies will be needed if we want to eliminate the disease, including the development of entirely new tools that offer a rapid and safe cure for river blindness."
Sabine Specht, Head of Filarial Clinical Programme at DNDi
DNDi aims to develop a safe, effective, affordable, and field-adapted 'macrofilaricidal' drug that can kill adult filarial worms and be used for individual patient treatment and to support the elimination of river blindness in Africa in areas that are difficult to treat.
Melchers, N.V, et al. (2019) Projected Number of People With Onchocerciasis–Loiasis Coinfection in Africa, 1995 to 2025. Clinical Infectious Diseases. doi.org/10.1093/cid/ciz647.